Is VivoSim Labs, INC. (VIVS) Halal?

NASDAQ Healthcare United States $4M
✗ NOT HALAL
Confidence: 90/100
VivoSim Labs, INC. (VIVS) is Not Halal under AAOIFI Standard 21. While the debt ratio of 19.7% is acceptable, the cash and interest-bearing securities ratio of 237.0% exceeds the 30% threshold. VivoSim Labs, INC. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from March 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 19.7%
/ 30%
237.0%
/ 30%
0.6%
/ 30%
97.22%
/ 5%
✗ NOT HALAL
DJIM 19.7%
/ 33%
237.0%
/ 33%
0.6%
/ 33%
97.22%
/ 5%
✗ NOT HALAL
MSCI 6.4%
/ 33%
77.2%
/ 33%
0.2%
/ 33%
97.22%
/ 5%
✗ NOT HALAL
S&P 19.7%
/ 33%
237.0%
/ 33%
0.6%
/ 33%
97.22%
/ 5%
✗ NOT HALAL
FTSE 6.4%
/ 33%
77.2%
/ 33%
0.2%
/ 50%
97.22%
/ 5%
✗ NOT HALAL

Financial Highlights

P/E Ratio
0.9
EPS
$1.76
P/B Ratio
1.0
EV/EBITDA
-0.1
EV: $748,898
Revenue
$144,000
Growth: 8.3%
Beta
1.3
High volatility
Current Ratio
2.4

Profitability

Gross Margin 0.0%
Operating Margin -10576.9%
Net Margin 0.0%
Return on Equity (ROE) -51.1%
Return on Assets (ROA) -132.5%

Cash Flow & Balance Sheet

Operating Cash Flow-$9M
Free Cash Flow-$9M
Total Debt$942,000
Debt-to-Equity18.3
Current Ratio2.4
Total Assets$15M

Price & Trading

Last Close$1.69
50-Day MA$1.97
200-Day MA$2.20
Avg Volume1.7M
Beta1.3
52-Week Range
$1.41
$5.30

About VivoSim Labs, INC. (VIVS)

CEO
Mr. Keith E. Murphy
Employees
14
Website
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NASDAQ
Market Cap
$4M
Currency
USD

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is VivoSim Labs, INC. (VIVS) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), VivoSim Labs, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is VivoSim Labs, INC.'s debt ratio?

VivoSim Labs, INC.'s debt ratio is 19.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 6.4%.

What are VivoSim Labs, INC.'s key financial metrics?

VivoSim Labs, INC. has a market capitalization of $4M, trailing P/E ratio of 0.9, and revenue of $144,000. Return on equity stands at -51.1%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.